Germany’s Federal Cartel Office approved Merck KGaA’s acquisition of Bio-Techne. This regulatory clearance satisfies a primary condition for the transaction to proceed.
The deal strengthens Merck’s position within the life science tools market. The integration will expand Merck’s product portfolio and research capabilities.
Merck expects the acquisition to drive future growth in its key business sectors. Financial terms and a closing timeline remain pending following this milestone.